Abstract
Modeling and simulation is poised to transform drug development across the entire life cycle from discovery to commercialization. For the biopharmaceutical industry, this transformation will enable knowledge-based decision making and foster new collaborative ways of working that will translate into more high-value treatments and increased development efficiencies. In the health care arena, where value for money is paramount, modeling and simulation will inform future health care planning and practice.